Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Rhea-AI Summary
Anixa Biosciences, a clinical-stage biotechnology company, appoints Dr. Sanjay Juneja, a renowned oncologist, to its Cancer Business Advisory Board. Dr. Juneja's expertise and influence in cancer prevention and treatment will benefit Anixa's mission in advancing cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
-
Rhea-AI Summary
Anixa Biosciences, Inc. announces its 2024 Annual Meeting of Stockholders to discuss its portfolio of oncology/immunology assets, including vaccines to prevent cancer and CAR-T cell therapy to treat cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
-
Rhea-AI Summary
Anixa Biosciences, Inc. announces CEO's participation in the 24th Annual World Vaccine Congress to discuss early-stage clinical results on a preventative breast cancer vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
Rhea-AI Summary
Anixa Biosciences, Inc. announces dose escalation for fourth patient in Phase 1 clinical trial of CAR-T therapy for ovarian cancer. The trial, in partnership with Moffitt Cancer Center, aims to demonstrate efficacy of FSHR-mediated CAR-T technology in solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
-
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) to present at 2024 NeauxCancer Conference, showcasing innovative cancer treatment approaches using the body's immune system. CEO Dr. Amit Kumar to meet investors and discuss the company's focus on cancer vaccine development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
-
Rhea-AI Summary
Anixa Biosciences, Inc. has announced that its collaborator, Cleveland Clinic, has received a 'Decision to Grant' notice from the Japan Patent Office for the patent application titled 'Ovarian Cancer Vaccines.' The patent extends the claims for this novel ovarian cancer vaccine technology to Japan, joining the European and U.S. patents awarded last year. Anixa is the exclusive worldwide licensee of the technology, which has shown promising results in pre-clinical studies. The vaccine has the potential to provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) to Present Business and Clinical Programs at Sidoti Micro-Cap Virtual Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.11%
Tags
-
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) to present business overview and clinical program updates at Biotech Showcase and J.P. Morgan Healthcare Conference 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
-
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) announced positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial, conducted in collaboration with Cleveland Clinic and funded by a U.S. Department of Defense grant, showed increased T cell immune response indicators and antibody production. The majority of patients developed antigen-specific T cell responses, and the vaccine was safe and well tolerated. Anixa plans to investigate additional dose levels and continue studying the vaccine's safety and immunologic effects in two additional patient cohorts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) to Release New Data from Ongoing Phase 1 Clinical Trial of Breast Cancer Vaccine at 2023 SABCS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
The current stock price of Anixa Biosciences (ANIX) is $3.08 as of November 15, 2024.
What is the market cap of Anixa Biosciences (ANIX)?
The market cap of Anixa Biosciences (ANIX) is approximately 100.1M.
What does Anixa Biosciences specialize in?
Anixa Biosciences specializes in developing vaccines and therapies aimed at the treatment and prevention of cancer, focusing on critical unmet needs in oncology.
What are the key components of Anixa's therapeutic portfolio?
Anixa's therapeutic portfolio includes an ovarian cancer immunotherapy program using CER-T technology and vaccine programs focused on preventing breast and ovarian cancers.
What recent achievements has Anixa Biosciences announced?
Recent achievements include receiving an 'Intention to Grant' notice from the European Patent Office for their ovarian cancer vaccine and presenting positive Phase 1 trial results for their breast cancer vaccine.
Who are some of Anixa Biosciences' key collaborators?
Key collaborators include Moffitt Cancer Center for immunotherapy programs and Cleveland Clinic for vaccine development.
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
Anixa's CER-T technology targets the follicle-stimulating hormone receptor (FSHR), which is specifically expressed on ovarian cells, offering a novel approach to treating solid tumors, unlike traditional CAR-T therapies.
What is unique about Anixa's cancer vaccine technology?
Anixa's cancer vaccine technology is unique in that it targets 'retired' proteins found to be expressed in specific forms of cancer, providing preemptive immune protection against emerging tumors.
Which forms of cancer are Anixa's vaccines targeting?
Anixa's vaccines are currently targeting triple-negative breast cancer (TNBC), the most lethal form of breast cancer, and ovarian cancer.
What are some recent clinical trial results from Anixa?
Recent clinical trial results include positive Phase 1 trial data for their breast cancer vaccine, showing antigen-specific T cell responses and an increase in immune-mediated biomarkers.
Does Anixa Biosciences participate in industry conferences?
Yes, Anixa actively participates in industry conferences such as the 2024 NeauxCancer Conference and the World Vaccine Congress to present their latest developments and foster collaborations.
Where can I find more information about Anixa Biosciences?
More information about Anixa Biosciences can be found on their website at www.anixa.com or by following them on social media platforms like Twitter, LinkedIn, Facebook, and YouTube.
Anixa Biosciences, Inc.
Nasdaq:ANIX
ANIX Rankings
ANIX Stock Data
100.08M
32.18M
5.05%
17.47%
1.85%
Biotechnology
Pharmaceutical Preparations
United States of America
SAN JOSE